Compare Charles River Laboratories Intl. Inc (CRL) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Atlassian Corporation PLC — how do they compare? Charles River Laboratories Intl. Inc trades at $285.62 (market cap $13.46B), while Atlassian Corporation PLC trades at $152.49 (market cap $39.10B). The key difference: Atlassian Corporation PLC is far larger — about 2.9× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Atlassian Corporation PLC nearer its low. Which is the better fit depends on your goals.
| CRL | TEAM | |
|---|---|---|
Market Cap | $13.46B | $39.10B |
Sector | Health | Technology |
52-Week High | $282.00 | $182.36 |
52-Week Low | $145.57 | $57.15 |
Enterprise Value | $16.30B | $39.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Atlassian (TEAM) trades at $152.49, up 0.41% on the day, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported strong Q4 2026 earnings, beating estimates with 28% revenue growth and achieving its first full year of GAAP profitability. Analyst sentiment is overwhelmingly positive, with 67% buy ratings and a consensus price target of $161.93.
The outlook is favorable given accelerating cloud revenue and AI platform adoption, though risks include high valuation multiples and potential growth deceleration. Net losses have narrowed significantly, but the stock's EV/EBITDA of 184.26 suggests premium pricing. Continued execution on enterprise deals and margin expansion are key for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
